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INTRODUCTION
Type 2 diabetes mellitus is characterized by a
chronic hyperglycemic state due to decreased insu-
lin sensitivity in target tissues, including skeletal
muscle, adipocytes and the liver, and/or impairment
of insulin secretion (1, 2). Obesity is a robustly pan-
demic and pathological disease and is responsible
for type 2 diabetes mellitus, hyperlipidemia and hy-
pertension (3). Increased serum levels of free fatty
acid (FFA) or triglyceride (TG) deteriorate hypergly-
cemia through peripheral insulin resistance, finally
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resulting in cerebral infarction and cardiovascular
disease (4, 5). Thus, in obese type 2 diabetes pa-
tients, treatment of hyperlipidemia is clinically im-
portant to prevent these comorbidities.
Buckwheat powder is used mainly for making
noodles in Asia, while much of buckwheat bran is
discarded. Recently, buckwheat has been developed
as a functional food for hypertension (6, 7), obesity
(7-9). The concentrated buckwheat bran extract
(BBE) reduced plasma glucose in streptozotocin-
induced type 1 diabetes rats (10) and KK-Ay type 2
diabetes mice (11). As for hyperlipidemia, in vivo
studies have been suggested that buckwheat pow-
der and protein decrease the level of serum choles-
terol or/and serum TG and enhance the exertion of
fecal neutral or acid sterol and bile acid (9, 12-16).
Insoluble fraction of buckwheat protein associates
with cholesterol and reduces micelle cholesterol
uptake in caco-2 cells (17). Recently, tartary BBE
reduce the serum level of total cholesterol and TG
in hyperlipidemic rats (18). However, all in vivo
studies do not examine the effect of lipid profile in
diabetic insulin-resistant animals.
In this study, we investigated the effect of com-
mon BBE on obese and diabetic KK-Ay mice and
found that BBE treatment decreased serum levels
of TG and fatty liver.
MATERIALS AND METHODS
Reagents
Dimethyl sulfoxide (DMSO) was purchased from
Nakalai Tesque (Kyoto, Japan). Glucose and insu-
lin were purchased from WAKO (Osaka, Japan). All
other chemicals were of analytical grade.
Preparation of extracts from buckwheat bran pow-
der
Common buckwheat (Fagopyrum esculentum
Moench) or buckwheat bran powder was manufac-
tured by a milling machine at TANI FOOD Co., Ltd.
(Ishii, Tokushima, Japan). Ten grams of buckwheat
bran powder was added to 50 ml of 80% methanol
(v/v) followed by stirring at room temperature for
one hour. And then the extracted solution was fil-
tered through filter paper (No. 5B, ADVANTEC,
Tokyo, Japan), and the filtrate was concentrated
and lyophilized at -80. The extracts were resolved
with 0.1% DMSO/PBS by sonication (BIORUPTOR
Cosmo Bio, Tokyo, Japan) and used for animal ex-
periments. The chemical composition of buckwheat
bran powder (moisture ; 4 g, protein ; 2.2 g, lipid ;
0.2 g, dietary fiber ; 89.5 g, sugar ; 2.4 g, ash ; 1.7 g,
rutin ; 0.76, quercetin ; 0.001) before methanol ex-
traction was determined according to the method
of AOAC (19), and dietary fiber compositions were
analyzed according to the method of Prosky et al.
(20).
Animals
Six-week-old KK-Ay mice (n=12) (CLEA Japan,
Tokyo, Japan) were randomly assigned to BBE treat-
ment groups (n=6) and control treatment groups
(n=6), respectively. Mice were maintained under
specific pathogen-free conditions with a 12-h light :
dark cycle at 252and 5510% relative humid-
ity. The mice were given a normal chow diet (Ori-
ental Yeast, Tokyo, Japan) and water ad libitum.
Mice were orally given 1 mg per 20 g body weight
BBE resolved with 100 μl 0.1% DMSO/PBS solution
or 0.1% DMSO/PBS per 20 g body weight as a con-
trol at 10 : 00 AM once per day for 6 weeks. Food
intake and body weight were measured and blood
samples after overnight starvation were collected
from the tip of the tail vein weekly at 10 : 00. Blood
samples were immediately centrifuged to collect
serum supernatant. Serum samples were stored
at -80until use for measurement of metabolic
parameters. Mice with overnight starvation were
sacrificed 6 weeks later under ether anesthesia to
obtain tissue samples of the liver, soleus muscle
and epididymal fat. The tissues were immediately
frozen in liquid nitrogen and stored at -80until
used for RNA preparation. The tissues were also
fixed immediately with 3.8% formaldehyde in phos-
phate buffered solution (37.5 mM NaH2PO4, 183
mM Na2HPO4) and stained with H&E stain. All stud-
ies were performed in accordance with the ethical
guidelines for animal experimentation of the In-
stitution of Health Bioscience, the University of
Tokushima and were approved by the institutional
review board of the animal ethics committee.
Oral glucose tolerance test (OGTT)
Six-weeks treated KK-Ay mice after sixteen hours
starvation were orally administered one gram of glu-
cose per kg of body weight. Blood samples were
collected from the tip of the tail vein at 0, 15, 30, 60
and 120 min. Whole blood glucose levels were meas-
ured by the FAD-glucose dehydrogenase method
with a GLUCOCARD GT-1820 device (ARKLAY,
Tokyo, Japan). The average of three measurements
at each time for each mouse was used for analysis.
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Measurement of lipid parameters
Plasma TG, FFA and total cholesterol concentra-
tions were measured by the GPO-DAOS method,
ACS-ACOD method and POD-DAOS method (Wako
Pure Chemical Industries, Osaka, Japan), respec-
tively. Lipid in the liver was extracted by the Folch
method (21), and TG in the liver was measured as
described above.
Quantitative real-time RT-PCR
Total RNA was extracted from the liver by using
an RNAiso (Takara, Kyoto, Japan) and then total
RNAs were reverse-transcribed using a Takara
PrimeScript RT reagent kit (Takara, Kyoto, Japan).
Quantitative real-time PCR was performed with the
LightCycler system (Roche Diagnostics, Switzer-
land) using Takara SYBR Premix Ex Taq II (Takara,
Kyoto, Japan). The following gene-specific primers
were used : ACC1 (sense : 5’ -aacatccccacgctaaacag-
3’ ; antisense : 5’ -aggtccggaaagagaccatt-3’), ACC2
(sense : 5’ -tggagtccatcttcctgtcc-3’ ; antisense : 5’ -g-
gacgccatacagacaacct-3’), SCD1 (sense : 5’ -gcgatac-
actctggtgctca-3’ ; antisense : 5’ -cccagggaaaccaggat-
att-3’), FASN (sense : 5’ -cccttgatgaagagggatca-3’ ;
antisense : 5’ -actccacaggtgggaacaag-3’), ChREBP
(sense : 5’ - cctcacttcactgtgcctca-3’ ; antisense : 5’ -
acaggggttgttgtctctgg-3’), SREBP1c (sense : 5’ -tactt-
cttgtggcccgtacc-3’ ; antisense : 5’ -tcaggtcatgttgga-
aacca-3’) and 18S ribosomal RNA (sense : 5’ -aaacg-
gctaccacatccaag-3’ ; antisense : 5’ -ggcctcgaaagagt-
cctgta-3’). After the PCR reaction, each PCR prod-
uct was confirmed for its single amplification by
analyzing a melting curve of the PCR products.
Statistical analysis
Data are expressed as meansSEM. Data were
analyzed by the unpaired Student’s t-test . A p -value
0.05 was accepted as statistically significant.
RESULTS
Treatment of BBE lowered serum level of TG and
fatty liver in KK-Ay mice
To determine the effect of BBE on KK-Ay mice,
we decided to use 1 mg BBE/20 g mice weights
treatment once a day, which dose is proved re-
cently by us to lower postprandial glucose (22).
Body weight in the BBE treatment group (30.37
1.76 g) was significantly decreased compared to that
in the control group (36.045.05 g) after 6-week
treatment (p=0.033). The gain of body weight in
the BBE treatment group (5.291.76 g) was sig-
nificantly decreased compared to that in the con-
trol group (11.073.72 g) after 6-week treatment
(p=0.004). Total food intake in the BBE treatment
group (160.69.7 g) and that in the control group
(177.921.2 g) were not significantly different (p=
0.85).
To determine the effect to insulin-resistance state,
we firstly examined OGTT. As shown in Figure
1, the level of blood glucose at 120 min after glu-
cose loading in the BBE group was significantly de-
creased. However, area under the curve of OGTT,
insulin tolerance test, or fasting blood glucose was
not changed in the BBE treatment group and that
in the control group (data not shown). Next, we
Figure 1. Oral glucose tolerance test in BBE treatment or control treatment groups.
Glucose was orally administered to twelve-weeks-old KK-Ay mice in the BBE group (black square) or control group (white circle)
and blood glucose levels were measured at 0, 15, 30, 60 and 120 min. Values are meansSEM (n=6). # : p0.05 .
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checked the levels of serum total cholesterol, TG
and FFA. Only the serum TG levels in the BBE
group were significantly lower than those in control
group (Figure 2). After sacrificed, the weights of
liver but not epididymal fat in the BBE group were
significantly lighter than those in the control group
(Figure 3). In addition, deposits in the liver in the
BBE group had almost disappeared (Figure 4A) and
TG content in the BBE group was significantly lower
than that in the control group (Figure 4B). Size of
fat cells and infiltration of mononuclear cells in the
BBE group were not different from those in the con-
trol group (Figure 4).
The mRNA expression of lipogenic genes was de-
creased in BBE-treated KK-Ay mice
To evaluate the decreased fat droplets of liver in
the BBE group, we examined the mRNA expres-
sion of gene related to lipolysis and β -oxidation.
The mRNA expressions of lypogenic genes, ACC2,
SCD1 and FASN in BBE groups were significantly
Figure 2. The serum levels of total cholesterol, TG and FFA.
Fasting serum level of total cholesterol (T-CHO), TG and FFA
of 12-weeks-old KKAy mice with BBE (black column) or control
treatment (white column) was examined. Data are meansSEM
(n=6). # : p0.05 .
Figure 3. Liver weight in the BBE group was decreased com-
pared to that in the control group.
Twelve-week-old mice in the BBE group (black column) and
control group (white column) were sacrificed and liver weights
(A) and amounts of epididymal fat (B) were examined. Values are
meansSEM (n=6). # : p0.05. N.S. : no significant difference.
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decreased compared to those in the control group
(Figure 5). The mRNA expressions of ACC1 in the
BBE group also tend to be decreased compared to
those in the control group (p=0.063) (Figure 5).
Moreover the mRNA expression of SREBP1c tran-
scription factor, which play a central role to lypo-
genesis in liver, was significantly decreased in the
BBE group (Figure 5). The mRNA expression of
ChREBP, which is activated by glucose and tran-
scripts lipogenic gene in liver, tended to be de-
creased in the BBE group (p=0.062) (Figure 5).
On the other hand, the mRNA expressions of pro-
teins involved in β -oxidation in liver, such as ACO,
CPT1α and PPARα in the BBE group were not
different to those in the control group (data not
shown).
Figure 4. BBE prevents development of fatty liver and TG accumulation.
Twelve-week-old mice in the BBE group and the control group were sacrificed. Livers and epididymal fat were stained with H&E stain
(A). Representative images from six mice in each group are presented. TG contents in livers in the BBE group and control group were
examined (B) (# : p0.05). Values are meansSEM (n=6).
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DISCUSSION
In previous studies, buckwheat powder and pro-
tein decrease the serum levels of total cholesterol
or/and TG in normal rat or rat fed high-fat diet
(9, 12-16). In this study, KK-Ay mice treated with
BBE showed decreased in body weight, level of TG
and fatty liver (Figures 2B, 3A and 4). Moreover,
the mRNA expression of lipogenic genes decreased
in the BBE group (Figure 5). The water soluble fi-
bers lower the absorption of sterols at intestine that
attributes to decrease the level of serum cholesterol
(23). The previous studies demonstrated that buck-
wheat powder and protein exert sterols and/or bile
Figure 5. mRNA expression of factors involved in liver lipogenesis.
The liver was obtained from 12-weeks-old KKAy mice in BBE groups (black column) or control groups (white column). Total RNA
was isolated from liver and was subjected to quantitative real - time RT-PCR with primers specific for ACC1/ 2, SCD1, FASN, ChREBP
or SREBP1c as described in the Materials and Methods section. Data were normalized by 18S ribosomal RNA (# : p0.05). Data are
meansSEM (n=6).
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acid in feces (9, 12-16). It was not reported that in-
soluble fibers has direct interaction with cholesterol
metabolism (24). The fibers of our BBE were almost
insoluble fibers, cellulose or hemi-cellulose, which
are eluated from methanol. In addition, tartary BBE
treatment does not decrease the absorption of cho-
lesterol and increase the cholesterol exertion to
feces (18). So we speculated that the effect of BBE
on the reducing serum level of TG, but not total
cholesterol (Figures 2A, B) was attributed to dimin-
ish the lipogenesis on hepatocyte (Figures 4, 5).
Mice in the BBE treatment group showed de-
creased serum levels of TG (Figure 2B) and recov-
ery of fatty liver (Figure 4). Those results were ex-
plained by the decrease of the mRNA expression of
lipogenic gene (Figure 5) and were as similar effects
as the study of buckwheat protein treatment in lipo-
genic rat (12). Excess of glucose enters into the
liver and metabolizes to acetyl-CoA. The acetyl-CoA
finally is used to TG synthesis via ACC and FASN
cascades (25). Along with palmitate, stearate is cata-
lyzed by SCD1 and finally metabolized to TG (26).
Insulin activates SREBP1c and glucose activates
ChREBP. Both transcription factors are transcripts
of lipogenic genes such as ACC and FASN (24).
KK-Ay mice with BBE treatments decreased both
of SREBP1c and ChREBP (Figure 5). The CPT-1α
is a rate-limiting enzyme for β -oxidation in the liver.
The transcription factors PPARα controls lipid me-
tabolism (27, 28). Although we examined the mRNA
expression of CPT-1α and PPARα, their expres-
sions was not different in the BBE group and in the
control group (data not shown). Those results sug-
gested that BBE treatment influenced lipogenesis,
but not β -oxidation in liver.
The previous report suggests that rutin treatment
(5 mg/kg body weight) reduces serum levels of
cholesterol (29). Oral administration of rutin to
streptozotocin-diabetic rats significantly decreases
the plasma concentration of total cholesterol and
TG (30). The amounts of rutin which they use are
much higher than those of our BBE treatment (14
μg per 1 mg BBE) (22). As already described, tar-
tary BBE treatment decreases the serum levels of
TG and total cholesterol, and also decreases the se-
rum and liver antioxidants (18). They speculate that
increased antioxidant activity after their BBE treat-
ment is derived from rutin. They analyzed the rutin
concentration of their BBE. Our amounts of rutin in
BBE were near those in their paper. It is suggested
that the suppression of oxidative stress decreases
pro-inflammation of liver and decreases serum level
of TG (31). We checked the mRNA expression of
pro-inflammatory adipokines, TNFα and MCP1, in
the liver. Both of them were not changed in the BBE
group and in the control group (data not shown).
From this result, we speculated that the effect of
BBE to decrease the serum levels of TG was not be
related to decrease the inflammation of liver.
As for the effect of BBE to insulin-resistance, the
level of blood glucose at 120 min after OGTT in the
BBE group was only significantly decreased com-
pared to that in the control group (Figure 1). In-
creased serum level of FFA has been known to
induce insulin resistance. It is suggested that hyper-
triglycemia and liver steatosis also induce insulin
resistance (32). We found that 1 mg of BBE has in-
hibitory activities of α -glucosidase (22). We specu-
lated that dose modification of BBE or combination
of BBE with anti-diabetic drugs might be more ef-
fective for insulin-resistance and hyperglycemia in
KK-Ay mice. The decrease of body weight gain in
the BBE group could be explained in part the de-
crease of liver weight. The weight of epididymal
adipocyte was not changed in the BBE group and
the control group. Therefore, we need to check the
effect of BBE to energy expenditures.
Taken together, the results indicated that chronic
treatment with BBE derivatives could have a bene-
ficial effect on hypertriglycemia in obese diabetic
animals. We are now investigating which phenolic
or non-phenolic component(s) of BBE, other than
rutin and quercetin, has an effect on TG metabolism.
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